Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

CHMP Withholds Support for Drugs Aimed at Duchenne Muscular Dystrophy, ALS

  • Post author:PacConAdmin
  • Post published:July 1, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The EU’s Committee for Medicinal Products for Human Use (CHMP) isn’t supporting two drugs intended to treat patients with amyotrophic lateral sclerosis (ALS) and Duchenne muscular — diseases that have…

Continue ReadingCHMP Withholds Support for Drugs Aimed at Duchenne Muscular Dystrophy, ALS

Legislative Update — Week of July 1, 2024

  • Post author:PacConAdmin
  • Post published:July 1, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

As the second session of the 118th Congress begins, FDAnews will track important pending legislation, that has been acted on since Dec. 31, 2023 to keep you updated on laws…

Continue ReadingLegislative Update — Week of July 1, 2024

Three Class I Recalls With Device Corrections, Not Removals, Including a Philips Ventilator

  • Post author:PacConAdmin
  • Post published:July 1, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Another Philips ventilator recall was deemed Class I by the FDA for an issue that has led to 15 reported injuries and one death. Source: Drug Industry Daily

Continue ReadingThree Class I Recalls With Device Corrections, Not Removals, Including a Philips Ventilator

FDA Approves Innovations in COPD Drugs, In-Office Hep C Test

  • Post author:PacConAdmin
  • Post published:June 28, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA has approved Verona Pharma’s Ohtuvayre (ensifentrine), the first inhaled maintenance chronic obstructive pulmonary disease (COPD) drug in more than two decades, and granted marketing authorization of a novel…

Continue ReadingFDA Approves Innovations in COPD Drugs, In-Office Hep C Test

Design of Drug-Device Combo Performance Measures is Subject of FDA Draft Guidance

  • Post author:PacConAdmin
  • Post published:June 28, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Assuring the consistent performance of a drug-delivery combination product through the outputs that measure that performance is the focus of an FDA draft guidance released July 1. Source: Drug Industry…

Continue ReadingDesign of Drug-Device Combo Performance Measures is Subject of FDA Draft Guidance

Regulatory Update — Week of June 24, 2024

  • Post author:PacConAdmin
  • Post published:June 28, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

This week, the FDA published a final guidance for small businesses on LDTs. The long-awaited draft guidance on diversity in clinical trials was also published. The agency modified its list…

Continue ReadingRegulatory Update — Week of June 24, 2024

Quick Notes: M&A and Collaborations — June 28, 2024

  • Post author:PacConAdmin
  • Post published:June 28, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

This edition of Quick Notes features announcements of Merck’s acquisition of EyeBio, J&J’s agreement with Numab Therapeutics, Becton Dickinson’s acquisition of Edwards Lifesciences Critical Care product group and Boston Scientific’s…

Continue ReadingQuick Notes: M&A and Collaborations — June 28, 2024

Philips BiPAP Sees Class I Recall Related to 952 Injuries, 65 Deaths

  • Post author:PacConAdmin
  • Post published:June 28, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Several Philips BiPAP devices and certain Baxter Life2000 ventilator systems are under FDA Class I recalls, the most serious type of recall, as use of the devices can result in…

Continue ReadingPhilips BiPAP Sees Class I Recall Related to 952 Injuries, 65 Deaths

CDRH, Gates Foundation Join Forces on Breath-Based Diagnostics

  • Post author:PacConAdmin
  • Post published:June 27, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Identifying disease biomarkers in rural and medically underserved populations through breath-based diagnostics devices is the goal of the FDA’s partnership with the Bill & Melinda Gates Foundation, CDRH announced Wednesday.…

Continue ReadingCDRH, Gates Foundation Join Forces on Breath-Based Diagnostics

FDA Changes CAR-T REMS Education, Adverse Event Reporting Requirements

  • Post author:PacConAdmin
  • Post published:June 27, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Changes to the Risk Evaluation and Mitigation Strategy (REMS) for all six approved CAR-T cell therapies remove the requirement for providers to engage in specific educational activities and allow them…

Continue ReadingFDA Changes CAR-T REMS Education, Adverse Event Reporting Requirements
  • Go to the previous page
  • 1
  • …
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • …
  • 144
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.